Recently, Porton Pharma Solutions Ltd.  announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ('Aojin Life Sciences').Porton will provide comprehensive CDMO services for Aojin in the CMC pharmaceutical research and GMP production of XDC conjugate drugs, targeting dual IND filings in China and the United States.

最近，波顿制药解决方案有限公司宣布与奥金生命科学（宜兴）有限公司（“奥金生命科学”）建立战略合作伙伴关系。Porton将为奥金提供全面的CDMO服务，用于CMC药物研究和XDC结合药物的GMP生产，针对中国和美国的双重IND申请。

Leveraging nearly two decades of end-to-end integrated CDMO service experiences, Porton has assembled a multidisciplinary project team that bridges drug substance and drug product technologies, integrating expertise in both small and large molecules. This strategic collaboration marks the beginning of a comprehensive and in-depth partnership between Porton and Aojin in the XDC conjugate drug sector.

凭借近二十年的端到端综合CDMO服务经验，Porton组建了一个多学科项目团队，将药物和药物产品技术联系起来，整合了小分子和大分子的专业知识。这一战略合作标志着Porton和Aojin在XDC结合药物领域全面深入合作的开始。

Together, we aim to promote the vigorous development of global XDC conjugate drugs, enabling the public’s early access to good medicines.About Aojin Life SciencesAojin Life Sciences (Yixing) Co., Ltd. is a biotechnology company dedicated to developing precise drug delivery technology platforms and XDC conjugated drugs.

我们共同致力于促进全球XDC结合药物的蓬勃发展，使公众能够尽早获得优质药物。关于奥金生命科学奥金生命科学（宜兴）有限公司是一家致力于开发精确药物输送技术平台和XDC偶联药物的生物技术公司。

It was jointly founded by Jiangsu Kingsly Pharmaceutical Co., Ltd. and Hong Kong OD Therapeutics, Ltd. The core technical management team brings over 30 years of experience in drug development with multinational corporations and biotech companies. Aojin Life Sciences possesses proprietary platform technology aimed at developing conjugated drugs that can deliver drugs in vivo with spatial and temporal control.

它由江苏金斯利制药有限公司和香港OD治疗有限公司共同成立。核心技术管理团队拥有与跨国公司和生物技术公司合作开发药物的30多年经验。奥金生命科学拥有专有的平台技术，旨在开发结合药物，可以通过空间和时间控制在体内递送药物。

By leveraging innovative technology, the company fundamentally improves the safety and efficacy of drugs, addresses urgent clinical challenges, and meets unmet clinical needs.About PortonWith over 4300 employees, Porton Pharma Solutions, a global company with R&D and GMP-compliant manufacturing facilities across the US, EU a.

通过利用创新技术，该公司从根本上提高了药物的安全性和有效性，解决了紧迫的临床挑战，并满足了未满足的临床需求。关于Porton拥有4300多名员工的Porton Pharma Solutions是一家全球性公司，在美国、欧盟和美国拥有研发和GMP合规制造设施。